Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals
- 20 March 2023
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 30 (6) , 544-550
Abstract
Research suggests a possible link between chronic infection with hepatitis C virus (HCV) and the development of Parkinson's Disease (PD) and secondary Parkinsonism (PKM). We investigated the impact of antiviral treatment status (untreated, interferon [IFN] treated, direct‐acting antiviral [DAA] treated) and outcome (treatment failure [TF] or sustained virological response [SVR]) on risk of PD/PKM among patients with HCV. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we applied a discrete time‐to‐event approach with PD/PKM as the outcome. We performed univariate followed by a multivariable modelling that used time‐varying covariates, propensity scores to adjust for potential treatment selection bias and death as a competing risk. Among 17,199 confirmed HCV patients, we observed 54 incident cases of PD/PKM during a mean follow‐up period of 17 years; 3753 patients died during follow‐up. There was no significant association between treatment status/outcome and risk of PD/PKM. Type 2 diabetes tripled risk (hazard ratio [HR] 3.05; 95% CI 1.75–5.32; p < .0001) and presence of cirrhosis doubled risk of PD/PKM (HR 2.13, 95% CI 1.31–3.47). BMI >30 was associated with roughly 50% lower risk of PD/PKM than BMI p = .0138). After adjustment for treatment selection bias, we did not observe a significant association between HCV patients' antiviral treatment status/outcome on risk of PD/PKM. Several clinical risk factors—diabetes, cirrhosis and BMI—were associated with PD/PKM.Keywords
Funding Information
- Centers for Disease Control and Prevention
- Gilead Sciences
This publication has 19 references indexed in Scilit:
- Hepatitis C virus infection as a risk factor for Parkinson diseaseNeurology, 2016
- Modeling Discrete Time-to-Event Data2016
- Body Mass Index and Risk of Parkinson’s Disease: A Dose-Response Meta-Analysis of Prospective StudiesPLOS ONE, 2015
- Parkinson s disease a reviewFrontiers in Bioscience-Scholar, 2014
- Improvement of Neurocognitive Function in Responders to an Antiviral Therapy for Chronic Hepatitis CHepatology, 2013
- Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort StudyClinical Infectious Diseases, 2012
- Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognitionJournal of Hepatology, 2012
- Increased risk of parkinsonism among patients with cirrhosis: a 7-year follow-up studyLiver International, 2011
- Hepatitis C Virus Neuroinvasion: Identification of Infected CellsJournal of Virology, 2009
- Evidence for a cerebral effect of the hepatitis C virusThe Lancet, 2001